Latest 8-K filings

Stran & Company, Inc. announced it will host a conference call on August 12, 2026, to discuss its financial results for the second quarter ended June 30, 2026, along with corporate progress.

CION Investment Corporation announced its second quarter 2026 financial results, reporting an increase in net asset value per share and a reduction in non-accrual investments, while also approving a $50 million increase to its share repurchase program.

Ocugen reports significant progress in its gene therapy pipeline for blindness diseases, including FDA clearance for a Phase 3 trial and a substantial financing round.

Agassi Sports Entertainment Corp. announces the launch of its global pickleball and padel platform initiative, aiming to become a leading network through acquisitions and partnerships.

Olenox Industries Inc. announced it has regained compliance with Nasdaq's periodic filing requirements after filing its delinquent Form 10-K and Form 10-Q.

Aemetis Inc. announced robust second quarter 2026 financial results, featuring a 20% year-over-year revenue increase to $62.7 million, driven by growth in its California Ethanol and Dairy RNG segments, alongside positive gross profit and a significant reduction in net loss.

CG Oncology announced its second quarter 2026 financial results, highlighting significant progress in its clinical development programs and a robust cash position sufficient through 2029.

Arteris, Inc. announced the appointment of Saurabh Sinha as its new Chief Financial Officer, effective September 8, 2026, succeeding Nick Hawkins.

Vystar Corporation announces a joint venture with Capital Realm, Inc. to acquire a 50% stake in r3alm, Inc., a compliance-focused AI and Web3 financial ecosystem.

Maximus reported strong third quarter fiscal year 2026 earnings per share of $2.22, exceeding the prior year's $2.16, despite a slight revenue dip, and reiterated full-year revenue guidance.

Ensysce Biosciences has completed the acquisition of Cy Biopharma, a clinical-stage biotech firm, and secured approximately $43 million in private placement financing to advance a neuroplastogenic therapy for CRPS.

Annexon's FORWARD study shows rapid, positive clinical responses in all Guillain-Barré Syndrome patients treated with tanruprubart within one week, reinforcing its potential as a first-in-class targeted therapy.

Charles River Associates announced an increase and extension of its credit facility to $400 million, supporting working capital and future growth initiatives.

NETSCOUT Systems, Inc. announced robust first quarter fiscal year 2027 financial results, exceeding expectations with significant revenue growth and improved profitability, while reaffirming its full-year financial outlook.

Vivani Medical has successfully dosed all participants in its Phase 1 SLIM-1 trial for NPM-139, a long-acting semaglutide implant.

Corbus Pharmaceuticals Holdings, Inc. announced its second quarter 2026 financial results, highlighting progress in its oncology and obesity drug development programs, with key data readouts and study initiations expected in September 2026.

White Mountains Insurance Group announced a 4% increase in book value per share for Q2 2026, driven by robust operating company performance and favorable investment returns.

Koppers Holdings Inc. reported a net loss of $147.5 million for Q2 2026, impacted by $215.8 million in impairment and restructuring costs, though sales increased to $520.1 million.

ASP Isotopes Inc. announced its subsidiary, Tetra4 Proprietary Limited, has entered into a new five-year take-or-pay contract for the sale of liquified natural gas (LNG) from the Virginia Gas Project.

Theriva Biologics has dosed the first patient in its VIRAGE2 Phase 2a clinical trial, evaluating a more frequent dosing regimen for its VCN-01 therapy in metastatic pancreatic cancer.

Delcath Systems reported Q2 2026 results, showing revenue growth and raising full-year revenue guidance, though adjusted EBITDA and operating cash flow saw a year-over-year decrease.

Chegg, Inc. announced its second quarter 2026 financial results, reporting a 51% year-over-year decrease in total net revenues to $51.8 million, alongside a net loss of $3.0 million.

Centrus Energy Corp. has signed a definitive contract with X-energy, LLC to supply low enriched uranium (LEU) and high-assay low-enriched uranium (HALEU), bolstering the U.S. nuclear fuel supply chain.

Ralph Lauren reported better-than-expected first quarter Fiscal 2027 results, with revenue up 14% and adjusted EPS of $4.59, leading to an increased full-year outlook.

Fox Corporation announced robust financial results for fiscal year 2026, highlighted by record revenue of $17.13 billion and a significant increase in Adjusted EBITDA, driven by major sporting events and streaming service growth.

Helix Energy Solutions Group, Inc. announced a significant turnaround in its second quarter 2026 financial performance, reporting a net income of $22.7 million and Adjusted EBITDA of $69.9 million.

Edgewise Therapeutics announced positive Phase 2 data for EDG-7500 in hypertrophic cardiomyopathy and completed a $2.65 billion sale of its sevasemten and muscular dystrophy business, sharpening focus on its cardiovascular pipeline.

BlackRock TCP Capital Corp. announced a significant portfolio sale of $523 million, which is expected to reduce its net leverage ratio to approximately 0.4x and enhance its investment capacity.

VivoSim Labs announced it has regained compliance with Nasdaq's minimum stockholders equity requirement and anticipates over 500% revenue growth in fiscal year 2027.

ALX Oncology announced second quarter 2026 financial results, reporting a reduced net loss and providing updates on its evorpacept and ALX2004 clinical programs, alongside leadership appointments and debt refinancing.